Press Releases

Jun 25, 2018

Approval for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome, two rare, severe childhood-onset epilepsies LONDON and CARLSBAD, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company

May 16, 2018

– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy – – Both doses significantly reduced drop seizure frequency in patients with poor seizure

Apr 19, 2018

LONDON and CARLSBAD, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW”, “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along

Apr 12, 2018

Long-Term Safety and Efficacy Data in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome to be Presented LONDON , April 12, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and

Mar 13, 2018
LONDON and CARLSBAD, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along